Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 68071-5160

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68071-5160). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5160 3)

Label for Venlafaxine Hydrochloride 37.5 mg extended release capsules by NuCare Pharmaceuticals, Inc. The package contains 30 capsules. It includes regulatory information with NDC 68071-5160-3, storage instructions to keep at controlled temperature 68-77°F, warnings to keep out of reach of children, and directions to consult the manufacturer’s label for ingredients.*

FDA Label Image

Figure 1: Effect Of Interacting Drugs On The Pharmacokinetics Of Venlafaxine And Active Metabolite O-desmethylvenlafaxine (odv). (Venlafaxine Fig1)

A pharmacokinetic interaction chart showing the fold change and 90% confidence interval for the analyte venlafaxine when coadministered with various interacting drugs. The chart plots Cmax and AUC changes relative to a reference value, with recommendations such as avoiding concomitant use or using caution for specific drugs including ethanol, diazepam, cimetidine, ketoconazole, indinavir, metoprolol, imipramine, and lithium.*

FDA Label Image

Figure 2: Effect Of Venlafaxine On The Pharmacokinetics Interacting Drugs And Their Active Metabolites. (Venlafaxine Fig2)

A pharmacokinetic (PK) interaction chart showing fold changes in Cmax and AUC for various interacting drugs with Venlafaxine Hydrochloride. The graph displays PK fold change values with 90% confidence intervals for drugs including ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium alongside recommendations for dose adjustment or use caution notes.*

FDA Label Image

Figure 3: Pharmacokinetics Of Venlafaxine And Its Metabolite O-desmethylvenlafaxine (odv) In Special Populations. (Venlafaxine Fig3)

A pharmacokinetic chart showing fold changes and 90% confidence intervals for venlafaxine under various special populations and conditions, including hepatic and renal impairment, CYP2D6 polymorphism, age over 60, and gender. The chart compares parameters such as Cmax, AUC, and ODV changes relative to reference values, accompanied by dosing recommendations for each condition.*

FDA Label Image

Chemical Structure (Venlafaxine Str)

Chemical structure of venlafaxine hydrochloride showing its molecular framework including a methoxy-substituted aromatic ring, cyclohexanol, and dimethylaminoethyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.